FeesSafety
Pluang+

BlackRock's BINC ETF outperforms in 2026 despite rate hikes, benefiting from active management and flexible strategy.

Market News
25 Sep 2026
Seeking Alpha
View Source
Bullish
BlackRock's BINC ETF outperforms in 2026 despite rate hikes, benefiting from active management and flexible strategy.

In 2026, BlackRock's iShares Flexible Income Active ETF (BINC) has shown strong performance despite a sharp 150 basis points rise in interest rates. The fund's active management strategy reduced its duration to 3.23 years and increased exposure to non-U.S. credits, which helped limit losses and improve flexibility. With 34% of its holdings below investment grade and a 5.5% SEC yield, BINC is well-positioned to gain if interest rates decline, as it already factors in four more Federal Reserve rate hikes. This makes BINC an attractive strategic investment amid current rate volatility.

BlackRock's iShares Flexible Income Active ETF (BINC) is noted in a context of rising interest rates. For readers following US stocks, here is Pluang's market snapshot as of Sep 25, 2026 19:11 WIB: out of 150 priced US stocks tradable on Pluang, 100 rose and 46 fell today. Notable movers include AMAT at USD 483.10 with a 1-day change of +1.87% and Pluang order activity of 87% Sell / 13% Buy, JBLU at USD 4.43 with a 1-day change of +1.84%, and DVN at USD 48.02 with a 1-day change of -1.80% and Pluang order activity of 43% Sell / 57% Buy.

More News

Over $815M in crypto liquidations hit as Bitcoin drops below $80K, Ether near $2,350

Over $815M in crypto liquidations hit as Bitcoin drops below $80K, Ether near $2,350

A major crypto market deleveraging saw over 118,000 traders liquidated, with $815-$821 million wiped from leveraged positions, mainly longs. Bitcoin fell below $80,000 and Ether approached $2,350, signaling a market correction and reduced confidence ...

Market News
Bearish
4 hours ago
Pumitamig plus docetaxel shows 36.7% response in advanced NSCLC after immunotherapy failure

Pumitamig plus docetaxel shows 36.7% response in advanced NSCLC after immunotherapy failure

BioNTech and Bristol Myers Squibb reported promising Phase 2 results for pumitamig combined with docetaxel in advanced non-small cell lung cancer (NSCLC) patients who progressed after immunotherapy plus chemotherapy. The treatment showed a confirmed ...

Company Fundamentals
Bullish
4 hours ago
US households' 1-year inflation expectations rise to 4.7% ahead of Fed policy meeting

US households' 1-year inflation expectations rise to 4.7% ahead of Fed policy meeting

US households' inflation expectations for the next year increased to 4.7% in October, the highest since May, while long-term expectations also rose. Consumer sentiment remained nearly unchanged, with mixed shifts in economic conditions and expectatio...

Market News
Neutral
4 hours ago
Tether freezes 2.21M USDT linked to CoinDCX after 15.99M USDT suspicious transfers detected

Tether freezes 2.21M USDT linked to CoinDCX after 15.99M USDT suspicious transfers detected

Tether has frozen 2,212,850.3 USDT across nine addresses connected to a security incident involving CoinDCX, following the detection of roughly 15.99 million USDT in unusual transfers. The investigation began after identifying these large suspicious ...

Market News
Bearish
4 hours ago
90% of Pump.fun contracts reverse-engineering done, full open source release urged by Oct 25

90% of Pump.fun contracts reverse-engineering done, full open source release urged by Oct 25

Andreessen Horowitz founder Shaw announced that 90% of the reverse-engineering work on all Pump.fun smart contracts is complete, with the remaining 10% expected to finish by October 25. Shaw emphasized the importance of making all contract code open ...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App